Please login to the form below
balugrastim
This page shows the latest balugrastim news and features for those working in and with pharma, biotech and healthcare.
EMA backs 15 new medicines for use in EU
tilmanocept) for the delineation and localisation of sentinel lymph nodes; and Teva's Egranli (balugrastim) to treat chemotherapy-induced neutropenia.
Latest news
-
Teva withdraws US filing for cancer biologic
FDA requests more data for balugrastim. Teva said this week it is "assessing its options" after withdrawing the US drug filing for long-acting white cell stimulator balugrastim. ... The FDA has agreed to work with Teva in designing any additional studies
-
Neulasta rival from Teva cleared in EU
Teva's biologics pipeline also includes reslizumab, a monoclonal antibody targeting interleukin-5 (IL-5) in phase III for moderate-to-severe asthma, and an albumin-fused G-CSF called balugrastim
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
Featured jobs
- Account Director or Senior Account Director
-
Salary TBC
- Senior Medical Writer, MedComms Agency
-
Salary TBC
- Account Director, Medical Communications & Events
-
£50 - 65, 000 according to skills and experience benefits
-
Vice President
-
Competitive Salary Offered
-
Consultant
-
competitive salary
-
Principal Medical Writer
-
£48 - 58, 000 according to skills and experience benefits
- Account Manager– Medical Communications
-
(Negotiable - depending on experience)
- Director of Scientific Services, Medical Communications, Six fig...
-
Six figure salary
Subscribe to our email news alerts
- New coronavirus sees drug developers scramble to develop a vaccine
- Sanofi completes acquisition of immuno-oncology specialist Synthorx
- Genital herpes vaccine candidate heads for human studies
- Roche’s SMA treatment risdiplam hits another clinical target
- Immuno-oncology, personalised medicine continues to drive pharma sector
- Roche's checkpoint inhibitor fails pivotal urothelial cancer trial
- Aurora boosts team with new hires and internal promotions
- NICE knocks back J&J’s depression nasal spray Spravato
- Acceleron rockets on positive mid-stage pulmonary arterial hypertension data
- NIH starts first trial of an antibody for malaria prevention
- GSK licenses its tuberculosis vaccine to Gates MRI
- A snapshot of Congenica
PMHub
Empowering Strategic Performance Ltd
OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...
Latest intelligence
- A snapshot of Congenica
- PME talks to CEO David Atkins...
- Data desires
- What are you looking to achieve with data and how are you preparing yourself to react to the results?...
- The balancing act that’s keeping pharma and biotech market access on its toes
- Pricing drugs and gaining reimbursement can be a real challenge for drug developers. Price it too high, and no one buys it. Price it too low, and it’s hard to...
Quick links
Infographics
